Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
From MaRDI portal
Publication:1929691
DOI10.1155/2012/317634zbMath1282.62235OpenAlexW2137656264WikidataQ58910958 ScholiaQ58910958MaRDI QIDQ1929691
André Rogatko, Mourad Tighiouart, Galen Cook-Wiens
Publication date: 9 January 2013
Published in: Journal of Probability and Statistics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1155/2012/317634
Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian inference (62F15) Sequential statistical design (62L05)
Related Items (3)
A continual reassessment method without undue risk of toxicity ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate
Uses Software
Cites Work
- Unnamed Item
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- Dose finding in drug development.
- Bayesian Optimal Designs for Phase I Clinical Trials
- Statistical Methods for Dose‐Finding Experiments
- Coherence principles in dose-finding studies
- Risk-Group-Specific Dose Finding Based on an Average Toxicity Score
- Continual Reassessment Method: A Likelihood Approach
- Designs foe phase i cancer clinical trials with differentiation of graded toxicity
- A Curve‐Free Method for Phase I Clinical Trials
- Bayesian Nonparametric Inference on the Dose Level with Specified Response Rate
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
- Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
- Monte Carlo sampling methods using Markov chains and their applications
This page was built for publication: Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
